Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis

Modern Rheumatology

Volumn 25, Issue 2, 2015, Pages 210-214

  Kizawa, Toshitaka ^a   Nozawa, Tomo ^a   Kikuchi, Masako ^a   Nagahama, Kiyotaka ^b   Okudela, Koji ^c   Miyamae, Takako ^a   Imagawa, Tomoyuki ^a   Nakamura, Tomoko ^d   Mori, Masaaki ^e   Yokota, Shumpei ^a   Tsutsumi, Hiroyuki ^f  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Odawara City Hospital   (Japan)

^e YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^f SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Childhood onset systemic lupus erythematosus; Intravenous cyclophosphamide; Lupus nephritis; Mycophenolate mofetil

Indexed keywords

ACICLOVIR; ALBUMIN; CHROMIUM; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; METHYLPREDNISOLONE ACETATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG DOSE REDUCTION; FEMALE; HERPES ZOSTER; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOCOMPLEMENTEMIA; INDUCTION CHEMOTHERAPY; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SCHOOL CHILD; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS; ANALOGS AND DERIVATIVES; DRUG COMBINATION; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; PATHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84924411614     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.950810     Document Type: Article

References (23)

1. Hiraki LT, Feldman CH, Liu J, Alarcón GS, Fischer MA, Winkelmayer WC, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012; 64(8): 2669-76.
2. Hafeez F, Tarar AM, Saleem R. Lupus nephritis in children. J Coll Physicians Surg Pak. 2008; 18(1): 17-21.
3. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991; 34(8): 945-50.
4. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004; 350(10): 971-80.
5. Cassidy TJ, Petty ER, Laxer MR, Lindsley M. Systemic lupus erythematosus. In: Textbook of Pediatric Rheumatology. 6th ed. Philadelphia: Saunders Elsevier, 2010. p. 314-343.
6. Pillkington C, Tucker LB, Isenberg DA. Systemic lupus erythematosus. In: Isenberg DA, Miller JJ, editors. Adolescent Rheumatology. London: Martin Dunitz, 1999. P.71-94.
7. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000; 43(8): 1801-1809.
8. Lehman TJ, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB, Kovalesky A. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr. 1989; 114(6): 1055-60.
9. Miyamae T, Nakajima S, Imagawa T, Itou S, Katakura S, Tomono N, et al. Improved maintenance therapy for juvenile lupus nephritis. Effect of introduction of an immunosuppressant in remission maintenance after methylprednisolone pulse therapy. Jap J Rheumatol. 2000; 39: 829-35 [in Japanese].
10. Yokota S, Mori M, Miyamae T, Itou S, Imagawa T, Ibe M. Cyclophosphamide pulse therapy for systemic lupus erythematosus. Jap J Pediatr Med. 1998; 30: 1666-8 [in Japanese].
11. Kurosawa R, Umebayashi H, Imagawa T, Katakura S, Mori M, Mituda T, et al. Diagnostic Characteristics of 38 children with systemic lupus erythematosus. J Jpn Pediatr Soc. 2006; 110: 398-405 [in Japanese].
12. Klippel JH. Indications for, and use of, cytotoxic agents in SLE. Baillieres Clin Rheumatol. 1998; 12(3): 511-27.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9): 1725.
14. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004; 15: 241-50.
15. Wu LH, Yu F, Tan Y, Qu Z, Chen MH, Wang SX, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013; 83(4): 715-23.
16. Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diff use Proliferative Lupus Nephritis. J Am Soc Nephrol. 2005; 16(4): 1076-84.
17. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011; 365(20): 1886-95.
18. Pereira T, Abitbol CL, Seeherunvong W, Katsoufis C, Chandar J, Freundlich M, Zilleruelo G. Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol. 2011; 6(9): 2192-9.
19. Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010; 69(12): 2083-9.
20. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47(2-3): 85-118.
21. Yap DY, Ma MK, Mok MM, Tang CS, Chan TM. Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology. 2013; 52(3): 480-6.
22. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5): 1103-12.
23. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005; 353(21): 2219-28.